Dr Boyd Kenway Cougle Jr, PHARMD | |
3633 Gray Ave, Adamsville, AL 35005-2238 | |
(205) 674-1400 | |
Not Available |
Full Name | Dr Boyd Kenway Cougle Jr |
---|---|
Gender | Male |
Speciality | Pharmacist |
Location | 3633 Gray Ave, Adamsville, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659335149 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | 14802 (Alabama) | Primary |
183500000X | Pharmacist | E09794 (Mississippi) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Dr Boyd Kenway Cougle Jr, PHARMD 2348 Garland Dr, Birmingham, AL 35216-3020 Ph: (205) 979-3321 | Dr Boyd Kenway Cougle Jr, PHARMD 3633 Gray Ave, Adamsville, AL 35005-2238 Ph: (205) 674-1400 |
News Archive
Vanderbilt researchers are reporting today that a drug currently used to treat type 2 diabetes could be just as effective in treating addiction to drugs, including cocaine.
The U.N. in February denied claims for compensation from 5,000 victims of the Haiti cholera epidemic, stating the claims were "non-receivable" under article 29 of the Convention on the Privileges and Immunities of the United Nations.
A team of researchers at the University of Minnesota have, for the first time, fully 3D printed an array of light receptors on a hemispherical surface. This discovery marks a significant step toward creating a "bionic eye" that could someday help blind people see or sighted people see better.
In a first-of-its-kind clinical trial, asthma researchers at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) will evaluate treatment guidelines for African American children and young adults with asthma.
Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.
› Verified 1 days ago
Matthew B Reamsma, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3633 Gray Ave, Adamsville, AL 35005 Phone: 205-674-1400 | |
Dr. Corey Nichols, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3633 Gray Ave, Adamsville, AL 35005 Phone: 205-674-1400 Fax: 205-674-1525 | |
Dr. Johnny J Brooklere, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3633 Gray Ave, Adamsville, AL 35005 Phone: 205-674-1400 | |
Dr. Anthony J Brooklere, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3633 Gray Ave, Adamsville, AL 35005 Phone: 205-674-1400 |